Starting October 1, 2023, a significant disruption in patient care is anticipated as Mass General Brigham’s Medicare Advantage plan will exclude the renowned Dana-Farber Cancer Institute from its network. This decision affects approximately 20,500 members, including long-term patients like 88-year-old Eldon Clingan, who has relied on the same oncologist for over two decades.
This shift not only raises concerns for patients who trust their specialists but also highlights the growing tensions between major healthcare providers and insurance networks. The exclusion of a leading cancer treatment center from a prominent Medicare Advantage plan could lead to increased patient anxiety and potential delays in care, as many will be forced to navigate new insurance options or seek alternative providers.
The implications of this change extend beyond individual patient experiences, potentially reshaping the competitive landscape among Boston’s healthcare institutions and influencing how Medicare Advantage plans negotiate with specialty providers in the future.
Use the database as your supply chain compass →
